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The muscle isoform of clathrin heavy chain, CHC22, has 85% sequence identity to the ubiquitously expressed CHC17, yet
its expression pattern and function appear to be distinct from those of well-characterized clathrin-coated vesicles. In
mature muscle CHC22 is preferentially concentrated at neuromuscular and myotendinous junctions, suggesting a role at
sarcolemmal contacts with extracellular matrix. During myoblast differentiation, CHC22 expression is increased, initially
localized with desmin and nestin and then preferentially segregated to the poles of fused myoblasts. CHC22 expression
is also increased in regenerating muscle fibers with the same time course as embryonic myosin, indicating a role in muscle
repair. CHC22 binds to sorting nexin 5 through a coiled-coil domain present in both partners, which is absent in CHC17
and coincides with the region on CHC17 that binds the regulatory light-chain subunit. These differential binding data
suggest a mechanism for the distinct functions of CHC22 relative to CHC17 in membrane traffic during muscle devel-
opment, repair, and at neuromuscular and myotendinous junctions.
INTRODUCTION
Skeletal muscle is composed of highly organized multinu-
clear cells or myofibers. Their internal organization is dic-
tated by the arrangement of actin and myosin myofibrils
with associated protein components, the former being an-
chored at regular intervals in Z-disks, for force generation
during muscle contraction (Clark et al., 2002). In addition to
the basic mechanical components, muscle function depends
on a number of specialized and housekeeping membrane
compartments and membrane traffic pathways (for review
see Towler et al., 2004). These membrane components are
also highly organized to coordinate with the contractile ap-
paratus. Muscle integrity further depends on specialized
membrane repair pathways to deal with chronic load-bear-
ing stress, and muscle development relies on specialized
membrane fusion processes as well as elaborate membrane
organization. An emerging theme in muscle cell biology is
that muscle-specific versions of ubiquitous membrane traffic
components are responsible for aspects of the specialized
membrane traffic involved in muscle function. Two exam-
ples include isoforms of amphiphysin and caveolin, which
have been implicated in T-tubule development in nonhu-
man species (Parton et al., 1997; Zhang and Zelhof, 2002) and
are defective in vertebrate muscle disease (Fischer et al.,
2003; Kubisch et al., 2003; Muller et al., 2003). Here we
characterize the distribution and function of the CHC22
isoform of clathrin heavy chain in skeletal muscle where it is
preferentially expressed (Long et al., 1996; Sirotkin et al.,
1996).
Clathrin is an essential component of several intracellular
membrane traffic pathways. Its self-assembling triskelion
structure allows the formation of clathrin-coated vesicles
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(CCVs) that sort membrane-bound nutrients, hormones, and
proteases during receptor-mediated endocytosis and or-
ganelle biogenesis (reviewed in Brodsky et al., 2001). This
familiar clathrin is formed by trimerization of the ubiquitous
isoform of clathrin heavy chain (CHC17) that is encoded on
human chromosome 17. Each CHC17 subunit is bound by a
regulatory light chain (LC) of which there are two forms in
vertebrates (LCa and LCb). The LCs control CHC17 assem-
bly in the cell and interact with a number of accessory
proteins involved in CCV function. The second isoform of
clathrin heavy chain, CHC22, was discovered during the
human genome project analysis of chromosome 22 (Kedra et
al., 1996; Long et al., 1996; Sirotkin et al., 1996; Holmes et al.,
1997). CHC22 mRNA was observed at high levels in skeletal
muscle, somewhat lower levels in cardiac muscle and testes,
and only at low levels in other tissues. The protein sequence
of CHC22 predicts 85% identity with CHC17 protein, sug-
gesting that they might have similar structural and func-
tional properties. However, initial studies of CHC22 indi-
cated that the two CHCs have different intracellular
distributions, some distinct biochemical properties and are
apparently regulated differently (Liu et al., 2001). These ob-
servations were primarily based on the properties of CHC22
expressed in vitro or expressed by transfection of HeLa cells
or analysis of the low levels of endogenous CHC22 in HeLa
cells. CHC22 was found to trimerize but it did not bind
clathrin LCs in vitro, nor colocalize with LCs in cells. Nor
did CHC22 Hub domain fragments (residues 1074–1640)
alter LC distribution as seen following expression of the
CHC17 Hub. In HeLa cells, CHC22 partially colocalized
with the membrane adaptors AP1 and AP3 and could be
immunoprecipitated with them, but showed no interaction
with AP2. All three AP complexes are involved in linking
CHC17 to membranes. Furthermore, CHC22 interaction
with intracellular membranes was sensitive to exposure of
cells to 20°C or cytochalasin D, treatments that do not per-
turb CHC17 membrane binding. Distinct function and reg-
ulation of the two clathrin isoforms were further indicated
by limited analysis of human skeletal muscle and myoblast
cultures. Both clathrins were expressed in the former and
staining revealed nonoverlapping distributions. CHC22 ex-
pression was minimal in undifferentiated myoblasts and
increased during myogenesis in culture, whereas CHC17
expression was constant throughout.
There are multiple specialized aspects of muscle mem-
brane traffic in which CHC22 could play a role. These in-
clude pathways that create and maintain muscle-specific
membrane compartments such as T-tubules and sarcoplas-
mic reticulum or pathways that create and maintain do-
mains of the sarcolemma that have organized contact with
extracellular matrix (ECM) at the neuromuscular junction
(NMJ), myotendinous junction (MTJ), and costameres. De-
fects in proteins involved in these matrix contact sites are
associated with a number of hereditary muscle diseases
(Clark et al., 2002; Ervasti, 2003). CHC22 could also poten-
tially function in the specialized organization of housekeep-
ing compartments. The Golgi apparatus and endocytic path-
way components have characteristic locations in myofibers
(Kaisto et al., 1999; Ralston et al., 1999), as do the more
specialized membrane traffic compartments such as those
that sequester the glucose transporter GLUT4 (Simpson et
al., 2001).
Muscle membranes must be organized during myogenesis
and repair, processes that also rely on specialized membrane
fusion pathways. In the studies reported here, we character-
ize the localization of CHC22 in mature skeletal muscle and
analyze its distribution during myogenesis and repair to
establish its relationship with muscle membrane organiza-
tion. Our findings are consistent with a role for CHC22 at
sites of membrane contact with the ECM. We also observed
a dramatic increase of CHC22 expression during muscle
regeneration, indicating a role in muscle repair. These prop-
erties of CHC22 were distinct from the behavior and distri-
bution of CHC17, so we searched for CHC22-binding pro-
teins that did not bind CHC17. One such protein identified
was sorting nexin 5 (SNX5), which is highly expressed in
skeletal muscle (Otsuki et al., 1999). In humans there are 22
SNXs, and all are characterized by a phox homology (PX)
domain that mediates lipid binding and potential membrane
association (Teasdale et al., 2001; Xu et al., 2001; Cozier et al.,
2002). SNX proteins have been implicated in membrane
cargo recognition and regulation of membrane traffic path-
ways (for a review see Worby and Dixon, 2002). We propose
that the interaction of CHC22 with SNX5 explains some of
the functional differences between CHC22 and CHC17, con-
tributing to the specialization of CHC22 in muscle mem-
brane pathways.
MATERIALS AND METHODS
Tissue Collection, Preparation, and Immunofluorescence
We obtained paraffin-embedded 5-m-thick tissue sections of human skeletal
muscle from postmortem cadavers from the Department of Pathology, UCSF
(Figures 1, A–C and G–L, and 2, A–C). The paraffin was removed by sub-
merging the samples twice, for 10 min each, in xylene in a glass slide holder
in a fume hood. Samples were rehydrated in washes of 100% ethanol for 3 min
and 70% ethanol for 3 min and 1 min in water. Before immunostaining,
sections were treated with 0.05% saponin at room temperature for 30 min to
unmask antigenic sites followed by three rinses in PBS. Blocking in a solution
of 0.02% SDS, 0.1% NP-40, 1% cold water fish skin gelatin (FSG), and 1% BSA
in PBS was carried out for 1 h at room temperature. Samples were incubated
with primary antibody for 3 h in blocking solution at 37°C under a coverslip,
followed by three 5-min-long washes at room temperature in blocking solu-
tion. The secondary antibody incubation was for 1 h in blocking solution at
37°C under a coverslip. Samples were then washed three times for 5 min each
in blocking solution on a rotating platform and rinsed twice in PBS and once
in water before being mounted in Vectashield mounting medium with DAPI
(Vector Laboratories, Burlingame, CA).
Rat skeletal muscle was harvested from newborn rats (Figures 1, D–F, and
2, G–I. Supplementary Data 1 and 3A-I) or from adult rats (Figure 2, J–O). The
tissue was fixed overnight in 4% paraformaldehyde in PBS and then washed
3 times in PBS (10 min each). Next the specimens were allowed to sink in a
15% sucrose solution before being embedded in optimum-cutting-tempera-
ture compound and frozen over chilled 2-methylbutane in liquid nitrogen.
Samples were stored at 80°C until sectioning. Sections, 10 m thick, were
collected on a cryostat at 23°C on superfrost/plus-coated slides (Fisher
Scientific, Pittsburgh, PA) and stored at 80°C. Samples were warmed to
room temperature for 15 min before blocking in 3% bovine serum albumin/
PBS for 30 min at room temperature. Primary antibody incubations were
carried out in 1% BSA/PBS for 2 h at room temperature under a coverslip,
followed by three 5-min washes in PBS on a rotating platform. Specimens
were then incubated with secondary antibodies for 1 h at room temperature
under a coverslip, followed by washing as before. Finally samples were rinsed
in distilled H2O and mounted in Vectashield containing DAPI (Vector Lab-
oratories).
Regenerating rat muscle was isolated on days 0, 1, 3, 5, 7, 10, 14, and 21 after
injection of the right tibialis anterior muscle of male Wistar rats with Taiwan
cobra venom, cardiotoxin (see Figures 5 and 6). Samples were collected at a
location near the injection site but where inflammatory infiltrate from me-
chanical damage as a result of the injection was not detected. Inflammation
was assessed by H&E staining. Muscle biopsies were frozen in chilled iso-
pentane cooled by liquid nitrogen and embedded. Serial cryosections were
made for a previous study of regenerating muscle (Hoshino et al., 2001, 2002a,
2003b, 2002c) and were maintained frozen until used for this study. Immu-
nofluorescence was carried out as described above for cryosections taken
from normal rat muscle.
Human muscle cryosections (Figure 2, D–F) were obtained from the lab of
Dr. Kimberly Topp (UCSF). Biopsies were taken from the vastus lateralis,
frozen immediately in isopentane, cooled with liquid nitrogen, and stored at
70°C until being sectioned. Cryosections were 10-m-thick cross sections
collected on Vecta-bond–treated slides (Vector Laboratories). Cryosections
were made during the course of a study on the effects on human muscle after
kidney transplantation (Topp et al., 2003). However, the sample shown in this
study was from a healthy control patient. Slides were warmed to room
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temperature for 15 min and then fixed lightly in 1% paraformaldehyde and
washed three times for 5 min in PBS. Samples were processed for immuno-
fluorescence as described for the cryosections above.
All rat tissue samples generated at UCSF were obtained through the com-
mittee of animal research tissue-sharing program.
Cell Culture and Transfection
Cell lines were grown at 37°C in a 5% CO2 incubator. Rat myogenic cells, L8
were derived by David Yaffe from embryonic (or newborn) rat hind limbs
(Yaffe and Saxel, 1977). The L8E63 cells are a clone derived from the L8 cell
line in the laboratory of Stephen Kaufman (Kaufman et al., 1980). L8E63 cells
were grown in DMEM supplemented with 10% horse serum, penicillin,
streptomycin, and 2 mM glutamine. They were passaged before reaching
confluency to maintain a fusogenic population. To initiate the process of
differentiation, cells were grown in low serum medium (2% horse serum
rather than 10%; see Figure 4, A–D). However, L8E63 cells would fuse
naturally if plated at 95–100% confluency (Figure 4, H–M). For immunfluo-
rescence studies cells were grown on collagen-coated cover slips to enhance
their adherent qualities. Stable HeLa-tet/on cells (Clontech, Palo Alto, CA)
containing the Tet response element, that express full-length or Hub CHC22
on addition of 2 g/l doxycycline, were maintained in DMEM supple-
mented with 10% Tet minus fetal bovine serum, penicillin, streptomycin, 2
mM glutamine, 0.4 mg/ml hygromycin B, and 0.2 mg/ml G418 (see Figure
7C; Liu et al., 2001). HeLa cells were cultured in DMEM (Life Technologies,
Rockville, MD) supplemented with 10% fetal bovine serum, penicillin and
streptomycin (Figure 7D). All transfections were carried out using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) following the manufacturers in-
structions.
Isolation and Immunofluorescence Analysis of Primary
Rat Muscle Fibers and Primary Myoblasts
Fibers were isolated from the musculus digitorum brevis muscle of adult rats
and cultured on Matrigel-coated dishes in DMEM  2% Serum Supreme 
penicillin/streptomycin/l-glutamine (see Figures 3, J–L and 4, E–G). The
fibers were fixed after overnight culture. Primary myotubes appeared after
5–7 days in culture in the presence of AraC to block cell division. The cells
were washed with PBS and fixed with 4% PFA for 30 min at room tempera-
ture. After washing with PBS the cells were permeabilized with 0.5% TX-100
for 10 min at room temperature. Cells were then washed three times in PBS
and nonspecific labeling was blocked for 30 min in 0.2% BSA  0.2% FSG in
PBS. Primary antibodies were diluted in blocking solution. Samples were
incubated overnight at 4°C. Samples were then washed with PBS three times
for 5 min each. Secondary antibodies were diluted into the block solution and
incubated at room temperature for 90 min (in the dark). After washing three
times for 5 min each with PBS the samples were mounted with Mowiol.
Samples were imaged by a Bio-Rad Radiance 2100 confocal microscopy
system with LaserSharp 2000 software (Hercules, CA). A 100, 1.3 oil im-
mersion objective was used with a 2.5 digital zoom camera to collect the
images. Images were further manipulated using Adobe Photoshop 5.0.
Immunofluorescence Labeling of Cells
Cells were rinsed twice in PBS, fixed in 4% paraformaldehyde for 20 min, and
washed three times in PBS followed by incubation in 50 mM ammonium
chloride for 10 min and three washes in PBS. Permeablization was carried out
using 0.2% (vol/vol) TX-100 for 4 min. Again cells were washed three times
in PBS, before blocking in 0.2% FSG (Sigma) in PBS for 10 min. Antibodies
were diluted in blocking solution and incubated with cells on cover slips for
Figure 1. CHC22 distribution in human and rat skel-
etal muscle. Normal human muscle tissue was fixed,
embedded in paraffin, and sectioned. Sections were pre-
pared for immunofluorescence and labeled for CHC22
with a specific polyclonal antibody (A and C, red; G and
I, red; J and L, red) and for CHC17 with mAb X22 (B and
C, green), monoclonal antibodies for myosin (H and I,
green), and desmin (K and L, green). Arrowheads indi-
cate the location of M-lines and the arrow indicates the
location of a Z-disk. Normal rat muscle tissue was fixed
and embedded in optimal cutting temperature com-
pound for cryosectioning. Sections were prepared for
immunofluorescence and labeled for CHC22 with a
polyclonal antibody (D and F, red) and for CHC17 with
a mAb X22 (E and F, green). Nuclei were stained with
DAPI (F, blue). Each row shows the same field viewed
with different filters and the right hand panel shows the
merged images. Scale bars in micrometers.
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20 min. Between primary and secondary antibody incubations cells were
washed three times with PBS/0.2% FSG. After incubations, cells were washed
three times in PBS/0.2% FSG, twice in PBS and once in water. Cover slips
were mounted in Vectashield containing DAPI (Vector Laboratories). All
steps were performed at room temperature (Figure 4, A–D and K–M, Sup-
plementary Data 2).
Figure 2. CHC22 concentrates at the neuromuscular junction of human and rat muscle. Normal human muscle tissue was sectioned and
prepared for immunofluorescence and labeled for CHC22 with a polyclonal antibody (A and C, red; D and F, red) and for neuromuscular
junctions using either antibody to acetylcholine receptor beta (AChR-Beta; B and C, green) or FITC-conjugated bungarotoxin (BngTx; E and
F, green). Normal rat muscle tissue was fixed and embedded for cryo-sectioning. Sections were prepared for immunofluorescence and labeled
for CHC22 with a polyclonal antibody (G and I, red; J and L, red; M and O, red) and for neuromuscular junctions (NMJs) using
FITC-conjugated BngTx (H and I, green; N and O, green) or antibody to acetylcholine receptor alpha (K and L, green). Arrows highlight
where muscle contacts tendon (I). DAPI was used to stain nuclei (F and I, blue). Each row shows the same field viewed with different filters
and the right-hand panel shows the merged images. Scale bars in micrometers.
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Fluorescence Microscopy
All images were acquired on a Deltavision Restoration microscope (Applied
Precision Instruments, Issaquah, WA) using a MicroMax 5 MHz cooled CCD
camera (Roper Scientific, Tucson, AZ) and running SoftWoRx (Applied Pre-
cision) deconvolution and data analysis software.
cDNA Constructs
Full-length CHC22 cDNA was cloned into the HindIII-SmaI restriction sites of
vector pEGFP-N3 from Clontech, for expression in L8E63 cells (see Figure 4,
H–J). Full-length human SNX5 cDNA was cloned into the vector pCMU
3XFLAG conferring three FLAG epitope tags at the N-terminus (see Figure 7,
C and D). For the mapping of SNX5/CHC22 interaction sites, clathrin heavy-
chain fragments were amplified from human cDNAs by PCR and cloned into
the EcoRI-SalI restriction sites of the pGBT9 bait vector (Clontech). SNX5 and
clathrin light-chain b fragments were amplified by PCR from the cDNA
clones identified in the library screen and cloned into the EcoRI-XhoI restric-
tion sites of the pACT2 prey vector (Clontech; see Figure 7, A and B).
Yeast Two-hybrid Screening
Two-hybrid screening was performed in the AH109 yeast strain. A human
skeletal muscle library with cDNAs cloned into the prey vector pACT2
(Clontech) was screened using the hub of CHC22 as bait in the vector pGBT9.
Yeast transformation and plate growth assays were performed following the
Clontech yeast protocols handbook. One hundred clones were screened. Once
positive clones were identified, plasmid DNA was isolated and transformed
into KC8 E. coli cells. DNA was purified from KC8 cells and sequenced.
Interactions were confirmed by cotransformation of yeast with the positive
clones (SNX5 238–404 and clathrin light-chain b 59–212) and CHC22 hub. The
minimal binding site of each partner was then determined by truncating each
fragment and cloning them into the respective bait or prey vectors, followed
by cotransformation and plate growth assay. Control fragments of CHC17 in
bait vector pGBT9 were generated previously in our lab (Chen et al., 2002). For
each indicated two-hybrid interaction, the cotransformation was repeated
three times, each time with at least three colonies being picked and assayed
(Figure 7B).
Coimmunoprecipitation Studies
HeLa cells that were permanently transfected to express full-length CHC22
(HeLa-Tet on-CHC22) or CHC22 Hub fragment (1074–1640; HeLa-Tet on-
CHC22 Hub) under the inducible tetracycline promoter were found to con-
stitutively express detectable levels of the transfected proteins. These cells
were transiently transfected with SNX5, tagged at the N-terminus with the
FLAG epitope (SNX5-FLAG). Cell lysates were prepared 16 h after transfec-
tion using buffer (0.3 ml/100-mm dish) containing 100 mM NaCl, 50 mM
HEPES, pH 7.4, 5 mM MgCl2, 0.5% NP-40, 1 mM PMSF, and 1 protease
inhibitor cocktail tablet (1/10 ml buffer, Roche, Indianapolis, IN). Lysates
were centrifuged at 14,000 rpm at 4°C for 10 min, and the supernatants were
kept for immunoprecipitations. For Figure 7C, lysates were incubated with
anti-CHC22 antibody for 2 h on a rotating wheel at 4°C, protein G-Sepharose
(PGS) 4 fast flow (Amersham Biosciences, Piscataway, NJ) was added for 1 h
and beads were washed three times in lysis buffer containing 1% TX-100
instead of NP-40. Samples were resolved by SDS-PAGE on 4–12% gradient
NuPAGE gels, using MOPS running buffer (Invitrogen). Proteins were trans-
ferred onto nitrocellulose membrane by Western blot and detected by anti-
body labeling and chemiluminescence. For Figure 7D, immunoisolations were
carried out from HeLa cell lysates using polyclonal antibodies specific for
CHC22 or CHC17 (-cons). After immunoprecipitating the clathrin heavy
chains, PGS beads were washed twice in lysis buffer and then incubated for
1 h with lysate of SNX5-FLAG-transfected HeLa cells or mock-transfected
HeLa cells. PGS beads were washed three times in lysis buffer. Samples were
resolved by SDS-PAGE on 4–12% gradient NuPAGE gels, using MOPS run-
ning buffer (Invitrogen). Proteins were transferred onto nitrocellulose mem-
brane by Western blot and detected by antibody labeling and chemilumines-
cence.
Antibodies
The antibodies used in this study were as follows: rabbit polyclonal and
monoclonal anti-CHC22 antibodies generated in our lab to the trimerization
domain of CHC22 (1521–1640) as described in Liu et al. (2001). Monoclonal
antibodies to CHC17 (TD.1 and X22) and to LCa (X16) and LCb (LCB.1) and
polyclonal antibodies against clathrin light chains (-cons) were generated in
the Brodsky lab (Blank and Brodsky, 1986; Acton and Brodsky, 1990; Nathke
et al., 1990). Antibodies to Ankrd2, FATZ, ZASP, and Telethonin were from
Georgine Faulkner, International Centre of Genetic Engineering and Biotech-
nology, Italy. Antibody to GLUT4 was from Jeffrey Pessin, University of
Michigan, Ann Arbor. Sources of antibodies recognizing the following adap-
tor proteins were AP1 (100.3) and AP2 (100.2) from Sigma, AP3 from Regis
Kelly, University of California, San Francisco, and AP4 from Juan Bonifacino,
NIH. The polyclonal antibody to GGA1 was from Margaret Robinson, Uni-
versity of Cambridge, England. The mouse mAb to synaptic vesicle protein 2
and ascites mouse monoclonal against 7 Integrin (H36) were from Robert
Edwards, University of California, San Francisco and Stephen Kaufman,
University of Illinois, Urbana, Illinois, respectively. Purchased antibodies
were as follows: monoclonal against myosin heavy chain of fast skeletal
muscle (MY-32), monoclonal against actin clone AC-40, monoclonal against
sarcomeric actin and anti-FLAG M2 mAb (Sigma), mouse monoclonal to
M-cadherin and rabbit polyclonal caveolin 3 (BD Transduction Laboratories,
Lexington, KY), mouse monoclonals to nestin, acetylcholine receptors alpha/
beta, integrin alpha 1 and dihydropyridine receptor (Chemicon International,
Temecula, CA), fluorescein conjugated -bungarotoxin (Molecular Probes,
Eugene, OR), mouse monoclonal to ryanodine receptor (Biomol), mouse
monoclonal to troponin I and dystrophin (AbCam, Cambridge, MA), mouse
monoclonal to TGN38 (Transduction Labs) and mouse to desmin (Zymed
Labs, South San Francisco, CA). Mouse monoclonal MyHC against embryonic
myosin (F1.652) was obtained from the Developmental Studies Hybridoma
Bank, University of Iowa. Secondary antibodies purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA) were fluorescein (FITC)-
conjugated AffiniPure donkey anti-mouse IgG, rhodamine red-X–conjugated
AffiniPure donkey anti-rabbit IgG, and Cy-5–conjugated AffiniPure donkey
anti-mouse IgG; those from Molecular Probes were donkey anti-mouse Alexa
488 and anti-rabbit Alexa 546.
RESULTS
CHC22 Concentrates at Neuromuscular and Myotendinous
Junctions
Antibodies that distinguish between human CHC22 and
CHC17 (Liu et al., 2001) were used to stain sections of mature
human and rat skeletal muscle. The differential distribution
of the two clathrins was confirmed in both species (Figure 1,
A–F) and both displayed a striated pattern of punctate stain-
ing, typical of intracellular vesicles. The distribution of
CHC22 relative to a number of muscle structural proteins
and proteins associated with muscle membranes was then
characterized in mature human skeletal muscle (Table 1,
Figures 1 and 2). Consistent with a lack of CHC17 colocal-
ization, CHC22 staining did not overlap with staining for
clathrin LCs. In contrast to what was previously observed in
HeLa cells, staining of human skeletal muscle showed no
overlap between CHC22 staining patterns and AP1, AP2, or
AP3 adaptors. This observation suggests that in muscle tis-
sue, where the expression of CHC22 is highest, it interacts
with tissue-specific proteins that occupy adaptor binding
sites and are most likely not expressed in HeLa cells. There
was also no colocalization of CHC22 with GLUT4 or of
CHC22 with T-tubule markers dihydropyridine receptor,
ryanodine receptor or caveolin 3 (Table 1). In longitudinal
sections of human muscle, the only structural protein that
showed partial colocalization with CHC22 was desmin.
Staining patterns of the two proteins overlapped at the
periphery of Z-disks (Figure 1, J–L). CHC22 did not colocal-
ize with myosin (Figure 1, G–I), actin, any Z disk compo-
nents analyzed or myofibrillar components (Table 1).
CHC22 appeared to localize to the same region as M-lines
(Figure 1, G and J, arrowheads), but the staining pattern was
consistent with vesicular staining in the region, rather than
characteristic of an M-line structural protein. CHC22 stain-
ing partially overlapped with labeling for dystrophin at the
sarcolemma (Table 1) and for acetylcholine receptors labeled
either by antibodies (Figure 2, A–C) or by bungarotoxin
(BngTx) binding (Figure 2, D–F). In transverse sections of
human skeletal muscle, it was apparent that CHC22 and
acetylcholine receptors were both concentrated at NMJs,
although CHC22 antibody labeling did not completely co-
incide with bungarotoxin (BngTx) binding to NMJs (Figure
2, D–F).
Localization of CHC22 to NMJs was confirmed in both
longitudinal and transverse sections of rat skeletal muscle
(Figure 2, G–O), where it also concentrated at typically cres-
cent-shaped structures labeled for acetylcholine receptors,
but without complete overlap with receptor labeling. In rat
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skeletal muscle sections, CHC22 distribution at the NMJ was
further characterized relative to CHC17, to the neuronal
synaptic vesicle 2 (SV2) protein and to nestin, an intermedi-
ate filament protein specific for NMJs and MTJs (Supple-
mentary Data 1; Carlsson et al., 1999; Vaittinen et al., 1999).
CHC22 was clearly on the opposite side of the NMJ to SV2
and was visible in cross-striations on the postsynaptic side.
CHC17 was not concentrated at NMJs as observed for
CHC22. Although CHC22 localized to the same NMJ struc-
tures as nestin, there was only partial colocalization of stain-
ing for the two proteins. In the longitudinal section of rat
muscle (Figure 2, G–I), the zigzag distribution of BngTx
labeling, characteristic of innervation patterns, was mirrored
by CHC22 labeling, again without staining being fully coin-
cident.
Also evident in the same section was a concentration of
CHC22 at the MTJ (arrows in Figure 2I). Specific localization
of CHC22 to the MTJ was further established by comparing
its distribution to CHC17, nestin and 7 integrin in this
region of rat skeletal muscle (Figure 3). The 7 integrin is
localized to sites of muscle contacts with ECM at both the
NMJ and MTJ (Burkin and Kaufman, 1999). As seen at the
NMJ, CHC17 distribution at the MTJ was uniform compared
with CHC22 and CHC17 was more evenly dispersed in
internal striations of skeletal muscle in the MTJ region (Fig-
ure 3, A–C). CHC22 and nestin or 7 integrin were concen-
trated at the MTJ, but the staining patterns were not com-
pletely coincident (Figure 3, D–I). Notable in these images is
the density of nuclei characteristic of the mononuclear ten-
don tissue that is contacted by muscle fibers at the MTJ.
CHC22 staining of isolated rat myofibers was also observed
to be concentrated at the MTJ, where it partially localized
with desmin, which interacts with nestin at the MTJ (Figure
3, J–L). In summary, analysis of human and rat skeletal
muscle sections with an antibody to human CHC22 revealed
that, in skeletal muscle from both species, CHC22 is present
in internal vesicles organized in a striated pattern. Also, in
both human and rat skeletal muscle, CHC22 is concentrated
at NMJs and MTJs and has a distinct distribution from
CHC17 clathrin, which is not preferentially concentrated at
these sites.
Polarized Distribution of CHC22 during Myogenesis
We have previously shown that CHC22 protein expression
is increased 50-fold in differentiating human myoblasts
(SKMC cells), whereas CHC17 expression remains constant
(Liu et al., 2001). To study this process morphologically,
CHC22 expression was characterized in the more robust
myogenic rat cell line, L8E63 (Figure 4 and Supplementary
Data 2). These cells were induced to differentiate by with-
drawal of serum from the culture medium and then double-
labeled with antibodies recognizing CHC22 and CHC17.
CHC22 was undetectable in the undifferentiated cells (Fig-
ure 4A). By day 2, CHC22 was visible and its distribution
pattern was clearly distinct from that of CHC17 (Figure 4B).
CHC22 localized to the poles of multinuclear myosacs
formed by these cells, whereas CHC17 was distributed
throughout the multinuclear cells and showed its character-
istic concentration at the trans-Golgi network (Figure 4, C
and D). CHC22 localization was also analyzed in a culture of
Table 1. Proteins analyzed for distribution relative to CHC22a
Human skeletal muscle L8 cells
Membrane transport CHC17 CHC17
markers Clathrin light chain a  b Clathrin light chain a  b
AP1 AP2
AP2 AP3
AP3 AP4
GLUT4 GGA1
TGN38
Skeletal muscle Caveolin 3 Caveolin 3
markers Dihydropyridine receptor Dihydropyridine receptor
Ryanodine receptor Ryanodine receptor
Myosin Myosin (fast)
Actin Troponin I
Alpha-actinin Alpha-tubulin
Sarcomeric actin Desminb
Desminb Nestinb
Dystrophinb Dystrophin
AChR alpha/betab
Integrin alpha 1
ZASP
Integrin alpha 7b
M-Cadherin
Alpha-actinin
Telethonin Telethonin
Ankrd2
ZASP
FATZ
aHuman skeletal muscle sections or L8E63 cells were labeled with monoclonal or polyclonal antibodies against the proteins listed and the
staining patterns compared to labeling with polyclonal anti-CHC22. In cases where double labeling was possible, comparison was made on
the same tissue section. All the antibody staining patterns were different from the CHC22 pattern. Those antibodies whose staining pattern
partially overlapped with CHC22 (in double label experiments) are indicated by footnote. L8E63 cells were examined for CHC22 co-
localization with the proteins indicated on several sequential days after serum withdrawal. AChR, acetylcholine receptor; ZASP, z-disk
associated protein; Ankrd2, ankyrin rich protein; FATZ, a filamin-, actinin-, and telethonin-binding protein of the Z-disc (expressed in the
same cells as CHC22 but no overlap); GLUT4, glucose transporter 4.
bPartial overlap.
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primary rat myoblasts isolated from rat foot skeletal muscle
(Figure 4, E–G). Myoblasts were induced to fuse by serum
reduction (in the presence of mitotic inhibitor AraC) and
then double-labeled for immunofluorescent staining with
antibodies to CHC22 or caveolin 3 (muscle-specific isoform
of caveolin). CHC22 localized to the poles of fused myo-
blasts (Figure 4, F and G), as seen in differentiating L8E63
cells (Figure 4, C and D), and its distribution was distinct
from that of caveolin 3 (Figure 4, E and G). The expression
levels of CHC22 detected during differentiation of L8E63
cells correlated with that expected from expression studies
of human CHC22 over the same differentiation time course
for the human myoblast cell line SKMC. However, the anti-
human CHC22 antibody used for these experiments, which
immunoprecipitates CHC22 from SKMC cells, was not able
to immunoprecipitate CHC22 from differentiated L8E63 cell
lysate, likely because of reduction in affinity for the rat
orthologue. The comparable immunofluorescence patterns
in Figures 1 and 2 indicate that the antibody used recognizes
the orthologous CHC22 protein in rat and human skeletal
muscle sections and does not recognize CHC17. The anti-
body did not recognize CHC17 in the L8E63 cells (Figures 4,
A–D). To confirm that it recognized the rat orthologue of
human CHC22, the anti-human CHC22 antibody staining of
Figure 3. CHC22 concentrates at myotendinous junctions. Rat muscle tissue was fixed and embedded for cryosectioning. Sections were
prepared for immunofluorescence and samples were double-labeled with antibodies to CHC22 (A and C, red; D and F, red; G and I, red),
and antibodies to CHC17 (B and C, green), nestin (E and F, green), and 7 integrin (H and I, green). Nuclei are stained with DAPI (C, F, and
I, blue). Regions where there are many nuclei but no staining with the other markers are tendons. Isolated myofibers were harvested from
rat skeletal muscle (musculus digitorum brevis) and cultured on matrigel. The fiber shown was fixed and labeled for CHC22 (J and L, red)
and desmin (K and L, green). Each myofiber has one NMJ and one MTJ. The MTJ region is shown. Each row shows the same field viewed
with different filters and the right-hand panel shows the merged images. Scale bars in micrometers.
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L8E63 was compared with the distribution of CHC22 fused
to green fluorescent protein (CHC22-GFP) transfected into
these cells (Figure 4, H–M). It can be seen that the transfected
CHC22-GFP protein (Figure 4, H–J) had the same distribu-
tion as the anti-CHC22 staining of untransfected cultures
differentiated at the same time (Figure 4, K–M). On days 1
and 3 of differentiation both patterns were polarized and
both became more diffuse on day 7 of differentiation, indi-
Figure 4. CHC22 expression increases during myogenesis and transiently acquires a polarized distribution. Rat L8E63 skeletal muscle cells
grown on collagen-coated cover slips were induced to differentiate by serum starvation at day 0. Cells were fixed on the subsequent days
indicated and processed for immunofluorescence, staining for CHC22 using a polyclonal antibody (A–D, green) and for CHC17 using mAb
X22 (A-D, red). Rat primary skeletal myoblasts grew out of the cultures described in the legend to Figure 3 (J-L). Shown are two cells that
appear to have recently fused to initiate myotube formation. Cells were fixed and labeled for caveolin 3 (E and G, green) and CHC22 (F and
G, red). The same field viewed with different filters and the right-hand panel shows the merged images (E–G). Rat L8E63 skeletal muscle cells
grown on collagen-coated cover slips were induced to differentiate by serum starvation at day 0. Cultures were transfected with GFP-tagged
full-length human CHC22 (CHC22-GFP) 24 h before fixation, and then they were fixed on day 1 (H), day 3 (I), and day 7 (J) after serum
starvation and processed for immunofluorescence analysis. The transfected CHC22 was visualized by direct fluorescence (H– J, green). For
comparison of parallel cultures, L8E63 cells were fixed on day 1 (K), day 3(L), and day 7 (M) after serum starvation and labeled with
polyclonal antibody against CHC22 (K–M, red). The degree of differentiation is evident from the formation of multinucleated myosacs, which
can be seen by the nuclear DAPI staining (H–M, blue). Scale bars in micrometers.
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cating a peak of polarized CHC22 activity at intermediate
stages of myogenesis. The polarized localization pattern for
CHC22 during these intermediate stages suggests a role for
the protein at sites where the growing multinuclear myo-
blast is attached to a substrate. This is consistent with
CHC22 localization to the MTJ and NMJ in mature muscle,
which are sites of muscle-ECM interaction. The comparable
staining patterns between rat and human mature skeletal
muscle and between the CHC22-GFP protein transfected
into L8E63 cells and that recognized by the antibody, along
with the identical time course of expression of the detected
protein in differentiating rat and human myoblasts, as well
as the lack of cross-reactivity of the anti-human CHC22 with
either rat or human CHC17, together indicate that the anti-
human CHC22 is recognizing the rat orthologue.
A number of structural proteins that function in muscle
differentiation and in mature muscle were tested for colocal-
ization with CHC22 during L8E63 myogenesis (Table 1 and
Supplementary Data 2). Most of the proteins tested had com-
pletely distinct staining patterns compared with CHC22 (Table
1), including T-tubule, myofibrillar, and Z disk proteins as well
as M-cadherin and dystrophin. Distribution of integrin 7 par-
tially overlapped with CHC22 staining at myotube tips, as
observed in mature skeletal muscle at MTJs. Two intermediate
filament proteins (desmin and nestin) also showed partial co-
localization with CHC22, restricted to early stages of differen-
tiation (Supplementary Data 2). By day 4, CHC22 distribution
was increasingly distinct from the two intermediate filament
proteins, both of which were less concentrated at the poles of
the multinuclear myosacs, relative to CHC22. Additionally, at
day 4, some cells expressed desmin and nestin but did not stain
for CHC22, indicating heterogeneity in the induced differenti-
ation of L8E63 cells. These staining patterns again suggest
localization of CHC22 to muscle contacts with the ECM. Con-
sistent with analysis of mature skeletal muscle, CHC22 staining
patterns did not overlap with antibodies labeling proteins as-
sociated with CHC17-coated vesicles, including the AP and
GGA1 adaptor molecules. There was also no coincidence with
the vesicle traffic marker TGN38. The lack of colocalization
with AP1 and AP3, which partially colocalized with CHC22 in
HeLa cells, again suggests tissue-specific proteins bind CHC22
when myogenesis is initiated, displacing potential interactions
with CHC17-binding proteins.
CHC22 Expression Is Increased in Regenerating Muscle
after Cardiotoxin Injection
An increase of CHC22 expression during myogenesis indi-
cated a role in muscle development, suggesting that CHC22
might also play a role in muscle repair. Tissue sections of
biopsies obtained from regenerating rat skeletal muscle
were therefore analyzed for CHC22 expression (Figure 5).
These biopsies were sampled at defined intervals of recov-
ery following cardiotoxin injection into rat tibialis anterior
muscle. Serial sections of the same biopsies were previously
analyzed for the expression patterns of a number of muscle
structural proteins (Hoshino et al., 2001, 2002a, 2002b, 2002c),
so these samples have already been established and charac-
terized as models of muscle regeneration. For comparison to
the regenerating muscle as a control, muscle was injected
with saline, sampled in the same manner, and then analyzed
for CHC22 expression. In transverse sections of control rat
muscle, faint sarcolemmal staining for CHC22 was observed
as well as concentrated staining at NMJs (Figure 5A). On day
1 after cardiotoxin injection, the tissue undergoes massive
necrosis as seen by the disorganized morphology of the
tissue (Figure 5B). CHC22 staining was also disorganized.
By day 3, satellite cells infiltrate the muscle and immature
regenerating myofibers with centrally located nuclei appear
(Figure 6). The intensity of CHC22 staining was increased at
this time point, relative to the earlier days of regeneration
(Figures 5C and 6, A, D, and G), and CHC22 staining was
predominantly in the interior of regenerating myofibers
with central nuclei (Figure 6, C, F, and I). On day 5 regen-
erating myofibers with small diameters make up the major-
ity of the affected tissue, and here CHC22 was observed
concentrated at the sarcolemmal perimeter of these myofi-
bers (Figure 5D). Days 7 and 10 reflect the growth of myo-
fibers into larger regenerating fibers and CHC22 staining
became less uniform and more localized at the sarcolemma
in regions where gaps between regenerating fibers were still
observed (Figure 5, E and F). It has been established that
reinnervation occurs around day 14 and at this time point as
well as day 21, CHC22 staining was concentrated at NMJs,
as seen in control tissue (Figure 5, A, G, and H), i.e., in
crescent shapes, polarized to one side of the myofiber.
CHC17 distribution was analyzed at all stages of regenera-
tion and in control muscle, and its distribution was uniform
compared with that of CHC22 (Figure 6, B and C, and
unpublished data). There were no stages of differentiation in
which CHC17 expression appeared to increase or in which
its distribution was polarized. To further analyze the stage
of regeneration in which CHC22 expression was dramati-
cally increased, muscle samples from day 3 after cardiotoxin
injection were stained for established markers of muscle
regeneration, M-cadherin (Figure 6, E and F; Matsuda et al.,
1983) and embryonic myosin (Figure 6, H and I; Matsuda et
al., 1983; Karsch-Mizrachi et al., 1989). Eighty-four percent of
fibers (n  100) that stained for embryonic myosin also
expressed CHC22, and 50% of CHC22-positive fibers (n 
100) also expressed M-cadherin. Neither marker had a stain-
ing pattern that substantially coincided with CHC22 label-
ing, although present in the same fibers. CHC22 staining
was also observed at the sarcolemma of large diameter
myofibers that appeared unaffected by cardiotoxin treat-
ment (Figure 6, G and I). The staining pattern for CHC22 in
regenerating muscle was compatible with repair functions
for CHC22 at two stages of muscle recovery. These include
potential roles at the interface between myofibers and satel-
lite cells where M-cadherin is observed and/or in reestab-
lishing fiber-fiber or fiber-nerve contacts. Furthermore, the
redistribution of CHC22 from uniform expression in regen-
erating fibers to concentrated sites at the NMJ was similar to
that reported for other proteins, such as nestin, involved in
NMJ organization and function, whose localization is de-
pendent on signals that occur upon reinnervation (Vaittinen
et al., 1999).
CHC22 Interacts with Sorting Nexin 5
The strikingly different distribution of CHC22 compared
with that of CHC17 in myoblasts and mature muscle and the
lack of colocalization of CHC22 with the regulatory clathrin
light-chain (LC) subunits or with CCV adaptor proteins in
muscle suggest there are specific binding partners for
CHC22 that are expressed in muscle. To identify such bind-
ing partners, the CHC22 Hub fragment (1074–1640) was
cloned into a bait vector for yeast two-hybrid screening and
was tested for interactions with a prey library derived from
human skeletal muscle. Candidate binding proteins identi-
fied were then tested by two-hybrid assay for lack of inter-
action with the CHC17 Hub fragment to determine which
ones might be involved in regulating the differential behav-
ior, distribution, and apparently different functions of the
two clathrins. A fragment of sorting nexin 5 (residues 238–
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404) was one of the prey constructs that interacted with
CHC22 Hub but not with CHC17 Hub (Figure 7, A and B).
Because sorting nexins are implicated in membrane binding,
vesicle cargo binding and membrane traffic (Worby and
Dixon, 2002), SNX5 was chosen for further analysis to con-
firm its status as a CHC22-binding protein. Furthermore,
published tissue distribution data for SNX5 reported differ-
ential high expression in skeletal muscle with secondary
expression in kidney, and expression in some transformed
cell lines but very little in HeLa cells (Otsuki et al., 1999),
supporting the possibility that SNX5 represents a functional
CHC22-binding partner in muscle.
Sequence analysis on the National Center for Biotechnol-
ogy Information Aceview website predicted that CHC22 has
a coiled-coil 4 (CC4) domain at residues 1459–1488 within
the Hub domain that is not predicted for CHC17. Two CC4
domains were already predicted for SNX5 at residues 259–
289 and residues 340–380 (Worby and Dixon, 2002). CC4
domains have been implicated in interactions with other
CC4 domains, so we hypothesized that they might mediate
SNX5-CHC22 binding. This was investigated by expressing
smaller fragments of each partner protein in bait and prey
vectors (Figure 7, A and B). When the N-terminal SNX5 CC4
domain was deleted from the SNX5 fragment, interaction
with CHC22 Hub was abrogated. Although a fragment com-
posed of that N-terminal CC4 domain alone (259–289) did
not interact with CHC22 Hub, a slightly larger fragment
extending 20 residues to either side (239–309) did interact
with CHC22 Hub, suggesting that this domain does mediate
SNX5-CHC22 binding but needs flanking residues to fold
properly. Removal of the CC4 domain in CHC22 also abro-
gated the SNX5-CHC22 interaction. However for CHC22 a
much longer fragment (CHC22 1267–1522), albeit still com-
prising the CC4 domain, was required for detecting an in-
teraction with SNX5. Notably, the CC4 domain in CHC22
overlaps with the LC-binding site in the equivalent region of
CHC17. Although an interaction between CHC22 and the
fragment of LCb (residues 59–212) comprising the CHC17
binding site (Chen et al., 2002) can be detected by yeast two
hybrid assay (Figure 7B), we have previously reported that
more sensitive two-hybrid assays reveal that CHC17 binds
more strongly than CHC22 to LCb (Liu et al., 2001). Here we
further demonstrate that CHC22-LCb binding was more
sensitive to protein truncation than the CHC17-LCb binding
(Figure 7B). This correlates with our published observations
that although CHC17 binding to LCs is detected in cells by
colocalization and coimmunoprecipitation and by protein
purification after coexpression (Liu et al., 2001), CHC22
binding to LCs is not detected in any of these protein assays.
Thus, CHC22 might have the capacity to bind LCs weakly,
Figure 5. CHC22 expression is increased in
regenerating rat muscle. Transverse section of
rat tibialis anterior muscle collected after sa-
line injection (A), as a control for injection of
cardiotoxin venom. Transverse sections of rat
tibialis anterior muscle collected on days 1, 3,
5, 7, 10, 14, and 21 after injection of cardio-
toxin venom (B–H). Tissue was fixed and pro-
cessed for immunofluorescence analysis of
CHC22 distribution using polyclonal anti-
CHC22. Scale bars in micrometers.
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but this is not observed at the protein level and furthermore,
the potential binding site for LCs is the SNX5 binding site, so
would be occupied in cells expressing SNX5.
The interaction between SNX5 and CHC22 was confirmed
at the protein level by coimmunoprecipitation from cells
expressing both proteins. Permanently transfected HeLa
cells that express full-length CHC22 or CHC22 Hub on
induction with doxycycline (Liu et al., 2001) also express
detectable levels of these proteins without induction, due to
leaky promoters. These cells were transiently transfected
with full-length SNX5 with a three-epitope FLAG tag at-
tached to its N-terminus (no antibody specific for native
SNX5 is available). FLAG-tagged SNX5 coimmunoprecipi-
tated with both full-length and Hub CHC22- compared with
mock-transfected cells (Figure 7C). The SNX5-FLAG protein
was not isolated in nonspecific immunoprecipitates using
rabbit preimmune serum (unpublished data). These trans-
fection experiments indicate that binding between CHC22
and SNX5 occurs in cells and suggest that SNX5 is a likely
partner for CHC22 in muscle, where both are expressed at
high levels. This interaction was shown to be specific for
CHC22 vs. CHC17 (Figure 7D). In this case the endogenous
heavy chains were immunoprecipitated from HeLa cells and
incubated with lysate from cells transfected with FLAG
tagged SNX5. The expressed SNX5 bound only to the im-
munoisolated CHC22 and not to the immunoisolated
CHC17. This experiment also indicates that even when
CHC22 and SNX5 are not coexpressed in the same cell,
binding between them is sufficiently avid that it can be
detected. The interaction of SNX5 with the CHC22 domain
that corresponds to the LC-binding domain of CHC17 sug-
gests a mechanism by which CHC22 could be regulated
differently from CHC17 and further suggests that SNX5
could serve as a membrane adaptor for CHC22.
DISCUSSION
We report here the first characterization of the CHC22 iso-
form of clathrin in skeletal muscle. CHC22 was found to be
concentrated at NMJs and MTJs in human and rat skeletal
muscle. Its expression was increased during myogenesis and
in regenerating muscle. This general pattern of CHC22 ex-
pression, including its polarization during myogenesis, sug-
gests a role for CHC22 at regions of the sarcolemma that are
involved in contact with ECM. Such regions are fundamen-
tal to muscle function and are vulnerable targets for hered-
itary muscle diseases. Morphological analysis of CHC22
further established its distinct distribution and function rel-
ative to the ubiquitous CHC17 clathrin. Our observation that
SNX5 binds CHC22 suggests a mechanism by which their
functions segregate and also implicates SNX5 in muscle
membrane traffic. These findings demonstrate that a novel
clathrin and a novel adaptor can contribute to membrane
traffic specialization in muscle tissue.
Distinct Regulation, Distribution, and Function of CHC22
Relative to CHC17
A recurring observation throughout this study is that
CHC22 and CHC17 have consistently distinct intracellular
localizations. The function of CHC17 is well characterized in
Figure 6. CHC22 expression localizes to regenerating fibers after cardiotoxin injection. Transverse sections of rat tibialis anterior muscle
collected on day 3 after injection of cardiotoxin venom (Hoshino et al., 2002a, 2002b, 2002c). Samples were double labeled for CHC22 (A and
C, red; D and F, red; G and I, red) and for CHC17 (B and C, green), M-cadherin (E and F, green), or embryonic myosin (H and I, green). The
regenerating fibers were characterized by centrally localized nuclei, visualized by DAPI staining in the merged panels (C, F, and I, blue). Each
row shows the same field viewed with different filters and the right hand panel shows the merged images. Scale bars in micrometers.
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organelle biogenesis and receptor-mediated endocytosis (re-
viewed in Brodsky et al., 2001). Because CHC22 does not
colocalize with any proteins associated with these conven-
tional clathrin pathways, its function in muscle appears to be
entirely different from that of CHC17. These conventional
CCV functions in muscle are most likely still carried out by
CHC17. The dramatic difference in distribution and expres-
sion levels of these two clathrin heavy chains is surprising
given the similarity in protein sequence (85%). On sequence
comparison of CHC22 and CHC17 it is difficult to pinpoint
functional domains, because the differences in protein se-
quence are dispersed throughout the entire protein. We have
previously shown that CHC22 trimerizes as does CHC17,
but that it does not interact with the clathrin LCs, as purified
proteins or in cells. Here we show that SNX5 binds to the
region in CHC22 where the light chain would normally bind
to CHC17 for negative regulation of clathrin assembly (Un-
gewickell and Ungewickell, 1991; Liu et al., 1995). This re-
gion has a predicted CC4 domain in CHC22 that is not
predicted for CHC17 and SNX5 did not interact with
CHC17. We propose that this CC4 domain mediates the
interaction between CHC22 and SNX5 because the partner
domain in SNX5 is the N-terminal CC4 domain present in
SNX5, which has two CC4 domains. SNX proteins are pre-
dicted to heterodimerize or homodimerize through their
CC4 domains. If the N-terminal CC4 domain in SNX5 binds
CHC22, the C-terminal CC4 domain could still bind other
proteins. One candidate is SNX1, which was recently shown
to interact with SNX5 (R. Teasdale and P. Gleeson, unpub-
lished results). Yeast two-hybrid analysis indicated that
CHC22 could potentially bind to clathrin LCs in the SNX5-
binding region. On the basis of the lack of detectable binding
between CHC22 protein and LCs in vitro and their lack of
colocalization with CHC22 in vivo, we suggest that SNX5
occupies the potential LC binding site with the resulting
effect that CHC22 is regulated differently than CHC17.
SNX5 is one of a subgroup of the SNX family that have a
70–110-residue SNX-PX domain and a C-terminal domain
with multiple CC4 domains (Teasdale et al., 2001). Both the
PX and the coiled-coil domains have been shown indepen-
dently to localize SNX5 to endosomal structures (Teasdale et
al., 2001). Membrane recruitment may also be mediated
through their interaction with cargo. Thus SNX5 could po-
tentially serve as a membrane adaptor for CHC22. In muscle
and in myoblasts, CHC22 did not colocalize with the adap-
tors that normally bind CHC17 (AP1, AP2, AP3, or GGA1).
In HeLa cells, we previously showed a potential interaction
between CHC22 and AP1 and AP3 but not AP2. We specu-
late that in muscle the AP-binding site might be obscured by
another binding protein so that membrane associations are
mediated differently, possibly through SNX5. Preliminary
yeast two-hybrid searches for proteins that specifically bind
the terminal domain of CHC22, which binds adaptors in
CHC17, revealed a number of potential binding candidates
to be explored. These findings and additional yeast two-
hybrid searches with the CHC22 Hub suggest that addi-
tional tissue-specific regulatory proteins that control the spe-
cialized function of CHC22 are likely to emerge.
Roles for CHC22 at Specialized Regions of the
Sarcolemma
Various specialized membrane regions and membrane
transport pathways are present in skeletal muscle (for re-
view, see Towler et al., 2004). These include the sarcolemma,
sarcoplasmic reticulum, T-tubules, NMJs, MTJs, costameres,
GLUT4 transport, and membrane fusion. Many muscle spe-
cific isoforms of proteins exist allowing these systems to
function in skeletal muscle. For example, caveolin 3 has been
implicated in T-tubule development (Parton et al., 1997).
CHC22 did not localize to T-tubules and does not colocalize
with caveolin 3 in primary rat myofibers or in muscle tissue;
therefore, a role in T-tubule biogenesis or maintenance was
ruled out. Similarly CHC22 did not colocalize with GLUT4
markers (Table 1). However its concentration at NMJs (Fig-
ures 2 and 5) and at MTJs (Figures 2 and 3) is evident.
NMJs are the site where the motor nerve innervates mus-
cle. Membrane traffic is polarized here and subneural nuclei
become specialized upon maturation of the NMJ to initiate
transcription of locally required proteins. These proteins are
in turn transported to their sites of action and CHC22 may
have a role in these specific transport pathways. The process
of innervation stimulates the localization of some proteins to
NMJs and it can also influence membrane traffic at NMJs
(Antony et al., 1995). The pattern of CHC22 distribution in
regenerating muscle was consistent with its localization be-
ing controlled by innervation. This could be the first exam-
ple of a membrane traffic protein being regulated in such a
way in skeletal muscle and would enable a role in special-
ized local protein transport. Membrane traffic at MTJs has to
respond to mechanical stress to mediate membrane repair,
thus MTJs also require stimulated localized membrane
transport, similar to that which occurs at NMJs and CHC22
could be involved in such pathways.
An alternative and not necessarily exclusive hypothesis
regarding CHC22 function can be proposed based on its
concentration at NMJs and MTJs and its partial colocaliza-
tion with desmin, nestin, and dystrophin. NMJs, MTJs, and
costameres (the sites where Z-disks meet the sarcolemma)
all represent organized regions of sarcolemma where muscle
contacts ECM proteins. The dystrophin/dystroglycan com-
Figure 7 (facing page). Sorting nexin 5 interacts specifically with
CHC22 through a coiled-coil 4 domain. (A) Diagrams indicating the
domains of CHC22, CHC17, SNX5, and clathrin light-chain LCb that
were tested as bait or prey in yeast two-hybrid experiments re-
ported in B. The fragments tested are delineated below the diagram
of each full-length protein. The shaded regions indicate predicted
coiled-coil 4 (CC4) domains in CHC22 and SNX5 that are absent in
CHC17 and LCb sequences. (B) Two-hybrid assays were performed
with the constructs shown in A cloned into the bait vector (pGBT9)
or prey vector (pACT2), as indicated. Interactions were measured
by plate growth assay and are indicated as () or (). Attenuated
growth was observed with those combinations marked “low.” (C)
Permanently transfected HeLa cells expressing full-length CHC22
(HeLa-Tet on-CHC22) or CHC22 Hub fragment (1074–1640; HeLa-
Tet on-CHC22 Hub; Liu et al., 2001) were transfected with full-
length SNX5 with a FLAG tag at the N-terminus (SNX5-FLAG) or
exposed to transfection conditions without DNA (Mock). After 16 h
cell lysates were prepared, CHC22 was immunoprecipitated with
specific polyclonal antibody, and immunoprecipitates were ana-
lyzed by immunoblotting. CHC22 and CHC22-Hub fragment were
detected with polyclonal anti-CHC22 and the coprecipitating SNX5
was detected with mAb to the FLAG epitope. Some endogenous
full-length CHC22 is detected in HeLa cells expressing CHC22 Hub.
(D) Clathrin heavy-chains CHC22 or CHC17 were immunoisolated
using specific polyclonal antibodies from HeLa cell lysates then
incubated with lysates of mock-transfected cells (lanes 1, 3, 5, and 7)
or lysates of cells expressing SNX5-FLAG (lanes 2, 4, 6, and 8).
Immunoisolated CHCs were detected by separately immunoblot-
ting the top half of lanes 1 and 2 or 3 and 4 with monoclonal
antibodies specific for CHC22 or CHC17, respectively. FLAG-
tagged SNX5 bound to CHC22 (lane 2) but not CHC17 (lane 4) was
detected by blotting the bottom half of lanes 1–4 with monoclonal
against the FLAG epitope. The whole cell lysates that were used as
a source of SNX5-FLAG or as control mock-transfected lysates are
shown in lanes 5–8 blotted for FLAG-tagged SNX5.
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plex is concentrated at these sites as well as integrin 71
(Clark et al., 2002). On the cytoplasmic side of the sarco-
lemma, these ECM contact molecules have extensive inter-
actions with adaptor and signaling proteins that are associ-
ated with a scaffold of intermediate filament proteins
(Michele and Campbell, 2003). Desmin is localized to all
three ECM contact regions and nestin, a desmin-binding
protein, concentrates more specifically at NMJs and MTJs
(Carlsson et al., 1999; Vaittinen et al., 1999; Clark et al., 2002).
The partial localization of CHC22 with desmin and nestin
both during myogenesis and in mature skeletal muscle sug-
gests that CHC22 might also have a scaffold function or
somehow contribute to the supramolecular organization of
these sites of ECM contact. The dramatic localization of
CHC22 to the poles of fused myoblasts, where they interact
with the culture dish, is also consistent with an organiza-
tional role at ECM contact sites.
Thus, our morphological analysis of CHC22 distribution
suggests it could either be involved in specialized protein
transport pathways that are shared by NMJs and MTJs or
could be involved in organizing proteins at these sites of
ECM contact. The intramuscular staining pattern of CHC22
is consistent with vesicular structures, and its association
with SNX5 is consistent with a role in membrane traffic. On
the other hand, the fibrous appearance of CHC22 staining at
the NMJ, suggests a potential structural role, as well. If
CHC22 self-assembles in a manner analogous to CHC17, it
could certainly play a role in membrane protein organiza-
tion as well as vesicle coat formation.
Predicted Roles for CHC22 in Muscle Regeneration and
Muscle Disease
The increase of CHC22 expression during muscle regenera-
tion suggests a role in reestablishing muscle function. Re-
generation involves reformation of contacts with the ECM
both at sites of reinnervation and at muscle reattachment
sites. The potential involvement of CHC22 in transport to
sites of muscle membrane stress at MTJs is also consistent
with its upregulation during regeneration. We have noted
the presence of myoD-binding sites upstream of the CHC22
gene (Towler and Brodsky, unpublished results). MyoD-
mediated transcription is essential both in myogenesis and
repair and the fact that CHC22 expression has the potential
to respond to this transcription factor supports its participa-
tion in these muscle functions. Further studies of CHC22
expression and regulation will contribute to our understand-
ing of muscle regeneration and stimulation of its expression
may contribute to therapeutic approaches to muscle disease.
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